• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Calcium channel blocker use not associated with increased risk of cancer

byDeepti Shroff, DMD, MSandDavid Wang
January 25, 2016
in Cardiology, Oncology
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In a population-based study of over 800 000 patients, calcium channel blocker (CCB) use was not associated with an increased risk of cancer compared to patients with no CCB exposure or patients on other anti-hypertensive medications.

Evidence Rating Level: 3 (Average)

Study Rundown: CCBs are one of the most widely prescribed medications worldwide for the management of angina, hypertension, and other cardiovascular diseases. However, previous studies have suggested that CCB exposure may interfere with apoptosis resulting in a potential increased risk of cancer. Previous retrospective reviews have demonstrated conflicting results regarding the association between CCB use and cancer. The purpose of this large, population-based study was to investigate the relationship between CCB use and the incidence of cancer.

The study reviewed medication use and health record data from over 800 000 patients in 2 national patient databases in the United Kingdom (UK) and compared the incidence of cancer between patients exposed to CCBs, patients with no exposure to CCB (non-CCB), and patients not exposed to CCB, but with exposure to an alternative antihypertensive medication (AHT). At the conclusion of the trial, CCB treatment was not associated with an increased incidence of cancer compared to those treated with non-CCB or AHT. This association was consistent across multiple cancer types, including breast, colon, and prostate. The results of this study support the hypothesis that CCB exposure is not associated with increased risk of cancer. The study was strengthened by a large sample size and a long follow-up period. However, the patient database is only representative of the UK population, which limits the generalizability to ethnically diverse populations.

Click to read the study in BMJ Open

Relevant Reading: Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?

RELATED REPORTS

Commonly cited medication triggers may not increase risk of microscopic colitis among older adults

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

In-Depth [retrospective cohort]: This study reviewed medication use data and patient outcomes of all adults aged 18 to 79 from the Clinical Practice Research Datalink (CPRD) and the National Cancer Registration System (NCRS) for the study period of 1996 to 2009. Overall, 865 647 patients were included and divided into 3 groups based on medication exposure: 1) patients exposed to CCB (n =150 750), 2) no exposure to CCB (n = 557 931), and 3) exposure to AHT (n = 156 966). CCB and AHT exposures were defined as having at least 1 prescription during the study time period. The primary outcome was the incidence of primary cancer and carcinoma in situ of known origin. At the conclusion of the trial, there were no significant differences between the incidence of cancer in the CCB cohort compared to the non-CCB or AHT groups. The adjusted hazard ratio (HR) for all cancers for the CCB group compared to the non-CCB and AHT groups were 0.88 (95% CI: 0.86 to 0.89) and 1.01 (95% CI: 0.98 to 1.04), respectively. In subgroup analysis, no significant differences were seen in the incidence of breast, colon, and prostate cancers between the CCB and AHT group.

Image: CC/wiki/MorgueFile

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: calcium channel blocker (CCB)
Previous Post

AAP addresses neonatal pain prevention

Next Post

Annual fecal immunochemical test screening associated with high sensitivity for colorectal cancer

RelatedReports

Prescription medicines collage: an amber pill bottle spilling tablets and capsules beside a pill-counting tray
Gastroenterology

Commonly cited medication triggers may not increase risk of microscopic colitis among older adults

July 4, 2025
Chronic Disease

Intranasal etripamil effective for conversion of paroxysmal supraventricular tachycardia

July 25, 2023
Collage for a seizure: an engraved brain crossed by a jagged teal ribbon, a pocket watch and a folded jacket
Chronic Disease

Angiotensin receptor blockers may reduce the incidence of epilepsy in patients with hypertension

October 24, 2022
#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes
StudyGraphics

#VisualAbstract: Lowering systolic blood pressure with antihypertensives may reduce new-onset type 2 diabetes

December 2, 2021
Next Post

Annual fecal immunochemical test screening associated with high sensitivity for colorectal cancer

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

CT of the chest, abdomen, and pelvis demonstrates low diagnostic yield in low-velocity trauma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.